Trials / Completed
CompletedNCT02694328
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 561 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 3831 | Daily dosing |
| DRUG | Olanzapine | Daily dosing |
Timeline
- Start date
- 2016-03-02
- Primary completion
- 2018-11-07
- Completion
- 2018-11-07
- First posted
- 2016-02-29
- Last updated
- 2020-02-10
- Results posted
- 2020-02-10
Locations
54 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02694328. Inclusion in this directory is not an endorsement.